Indivior's Barlow acquires 41,652 shares in merger
Converted awards remained subject to substantially the same terms and conditions, including vesting, except performance stock units became time-vesting restricted stock units.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Indivior Pharmaceuticals, Inc. (renamed Supernus, Inc. in connection with the merger) reports that director Carrolee Barlow acquired 41,652 common shares on November 2, 2026, in exchange for Barlow's former Supernus Pharmaceuticals shares. Each outstanding Supernus Pharmaceuticals share converted into the right to receive 1.5401 shares of Indivior common stock; Barlow received no cash consideration other than cash in lieu of a fractional share. Outstanding equity awards were also assumed and converted into corresponding awards. Barlow's 4,603 restricted stock units settle in common stock upon vesting on February 18, 2027.
Insider Trade Summary
Other: 158,639 shares
Other
11 txns
Insider
Barlow Carrolee
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Restricted Stock Units F2, F3 | 4,603 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 15,729 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 19,138 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 14,330 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 11,342 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 10,545 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 9,691 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 12,708 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 11,236 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 7,665 | $0.00 | $0.00 |
| Other | Common Stock F1 | 41,652 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 4,603 contracts (Direct);
Director Stock Option (right to buy) — 112,384 contracts (Direct);
Common Stock — 41,652 shares (Direct)
Footnotes (3)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
- F2. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except that performance stock unit awards were converted into time-vesting restricted stock units.
- F3. These restricted stock units are settled in common stock upon vesting, which occurs on February 18, 2027.
Key Figures
Common shares acquired: 41,652 shares
Merger exchange ratio: 1.5401 shares per share
Restricted stock units: 4,603 units
+2 more
5 metrics
Common shares acquired
41,652 shares
Received in the merger on November 2, 2026
Merger exchange ratio
1.5401 shares per share
Indivior common shares for each outstanding Supernus Pharmaceuticals common share
Restricted stock units
4,603 units
Settle in common stock upon vesting on February 18, 2027
Converted director stock option shares
15,729 underlying shares
Exercise price $37.76 per share; expiration June 27, 2028
Converted director stock option shares
19,138 underlying shares
Exercise price $23.87 per share; expiration February 22, 2029
Key Terms
exchange ratio, equity award, restricted stock units, time-vesting restricted stock units, +1 more
5 terms
exchange ratio financial
"multiplied by the 1.5401 exchange ratio (rounded down)"
The exchange ratio is the number used to decide how many shares of one company you get for each share you own in another company during a merger or acquisition. It’s like a recipe that tells you how to swap shares fairly, ensuring both companies’ values are balanced. This ratio matters because it determines how ownership divides between the companies' shareholders.
equity award financial
"each outstanding Supernus Pharmaceuticals equity award was assumed"
An equity award is a form of pay where a company gives employees, executives or other stakeholders the right to own or buy company shares—either immediately or after meeting certain conditions. Think of it like receiving slices of the company pie now or coupons to claim slices later; it matters to investors because it affects ownership dilution, executive incentives and reported compensation costs, and signals how management is being rewarded and retained.
restricted stock units financial
"These restricted stock units are settled in common stock upon vesting"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
time-vesting restricted stock units financial
"converted into time-vesting restricted stock units"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How were Carrolee Barlow's equity awards converted in the INDV merger?
Indivior assumed and automatically converted outstanding Supernus Pharmaceuticals equity awards into corresponding awards, applying the 1.5401 exchange ratio to share amounts and rounding down. Per-share exercise prices were divided by the ratio and rounded up to the nearest whole cent. Converted awards retained substantially the same terms and vesting, except performance stock units became time-vesting restricted stock units.
AI-generated analysis. How Rhea-AI works. Not financial advice.
